Persistent low-Level viremia in persons living with HIV undertreatment: An unresolved status

References

• Thiébaut R, Morlat P, Jacqmin-Gadda H, et al. Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d’Epidémiologie du SIDA en Aquitaine (GECSA). AIDS. 2000;14(8):971–978.
   PubMed Web of Science ®Google Scholar
• Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853–860.
   PubMed Web of Science ®Google Scholar
• Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.
   PubMed Web of Science ®Google Scholar
• Guidelines for the use of antiretroviral agents in adults and adolescent living with HIV. https://aidsinfo-nih.gov/contentfiles/vguidelines/adultandadolescentgl.pdf. Accessed 2020 Jan 14
   Google Scholar
• EACS. European AIDS clinical society. European guidelines for treatment of HIV infected adults in Europe. Versión 10.0 2019 https://eacsociety.org/files/2019_guidelines-10.0_final.pdf. Accessed 2020 Jan 14
   Google Scholar
• Palmer S, Wiegand AP, Maldarelli F, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 2003;41(10):4531–4536.
   PubMed Web of Science ®Google Scholar
• Maldarelli F, Palmer S, King MS, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog. 2007;3(4):e46.
   PubMed Web of Science ®Google Scholar
• Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A. 2008;105(10):3879–3884.
   PubMed Web of Science ®Google Scholar
• Havlir DV, Strain M, Clerici M, et al. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol. 2003;77(20):11212–11219.
   PubMed Web of Science ®Google Scholar
• Greub G, Cozzi-Lepri A, Ledergerber B, et al. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS. 2002;16(14):1967–1969.
   PubMed Web of Science ®Google Scholar
• Taiwo B, Gallien S, Aga E, et al. Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy. J Infect Dis. 2011;204(4):515–520.
   PubMed Web of Science ®Google Scholar
• García-Gascó P, Maida I, Blanco F, et al. Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome. J Antimicrob Chemother. 2008;61(3):699–704.
   PubMed Web of Science ®Google Scholar
• Havlir DV, Bassett R, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination hiv therapy. JAMA. 2001;286(2):171–179.
   PubMed Web of Science ®Google Scholar
• Karlsson AC, Younger SR, Martin JN, et al. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS. 2004;18(7):981–989.
   PubMed Web of Science ®Google Scholar
• Delaugerre C, Gallien S, Flandre P, et al. Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients. PLoS One. 2012;7(5):e36673.
   PubMed Web of Science ®Google Scholar
• Swenson LC, Min JE, Woods CK, et al. HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure. AIDS. 2014;28(8):1125–1134.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Serna A, Min JE, Woods C, et al. Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals. Clin Infect Dis. 2014;58(8):1165–1173.
   PubMed Web of Science ®Google Scholar
• Geretti AM, Smith C, Haberl A, et al. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy. Antivir Ther. 2008;13(7):927–936.
   PubMed Web of Science ®Google Scholar
• Sungkanuparph S, Groger RK, Overton ET, et al. Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy. HIV Med. 2006;7(7):437–441.
   PubMed Web of Science ®Google Scholar
• Ostrowski SR, Katzenstein T, Thim P, et al. Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy. J Infect Dis. 2005;191(3):348–357.
   PubMed Web of Science ®Google Scholar
• Ostrowski SR, Katzenstein TL, Pedersen BK, et al. Residual viraemia in HIV-1-infected patients with plasma viral load or=20 copies/ml is associated with increased blood levels of soluble immune activation markers. Scand J Immunol. 2008;68(6):652–660.
   PubMed Web of Science ®Google Scholar
• Mavigner M, Delobel P, Cazabat M, et al. HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS One. 2009;4(10):e7658.
   PubMed Web of Science ®Google Scholar
• Leierer G, Grabmeier-Pfistershammer K, Steuer A, et al. Factors associated with low-level viraemia and virological failure: results from the Austrian HIV cohort study. PLoS One. 2015;10(11):e0142923.
   PubMed Web of Science ®Google Scholar
• Vandenhende M-A, Perrier A, Bonnet F, et al. Risk of virological failure in HIV-1-infected patients experiencing low-level viraemia under active antiretroviral therapy (ANRS C03 cohort study). Antivir Ther. 2015;20(6):655–660.
   PubMed Web of Science ®Google Scholar
• Joya C, Hyun won S, Schofield C, et al. Persistent low-level viremia while on antiretroviral therapy is an independent risk factor for virologic failure. Clin Infect Dis. 2019;69(12):2145–2152.
   PubMed Web of Science ®Google Scholar
• Boillat-Blanco N, Darling K, Schoni-Affolter F, et al. Virological outcome and management of persistent low-level viraemia in HIV-1-infected patients: 11 years of the Swiss HIV cohort study. Antivir Ther. 2015;20(2):165–175.
   PubMed Web of Science ®Google Scholar
• Vandenhende MA, Ingle S, May M, et al. Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients. AIDS. 2015;29(3):373–383.
   PubMed Web of Science ®Google Scholar
• Fleming J, Mathews WC, Rutstein RM, et al. Low-level viremia and virologic failure in persons with HIV infection treated with antiretroviral therapy. AIDS. 2019;33(13):2005–2012.
   PubMed Web of Science ®Google Scholar
• Laprise C, de Pokomandy A, Baril J-G, et al. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation. Clin Infect Dis. 2013;57(10):1489–1496.
   PubMed Web of Science ®Google Scholar
• Bernal E, Gómez JM, Jarrín I, et al. Low-Level viremia is associated with clinical progression in HIV-Infected patients receiving antiretroviral treatment. J Acquir Immune Defic Syndr. 2018;78(3):329–337.
   PubMed Web of Science ®Google Scholar
• Hermans LE, et al. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study. Lancet Infect Dis. 2018;18(2):188–197.
   PubMed Web of Science ®Google Scholar
• Elvstam O, Medstrand P, Yilmaz A, et al. Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment. PLoS One. 2017;12(7):e0180761.
   PubMed Web of Science ®Google Scholar
• Sudjaritruk T, Teeraananchai S, Kariminia A, et al. Impact of low-level viraemia on virological failure among Asian children with perinatally acquired HIV on first-line combination antiretroviral treatment: a multicentre, retrospective cohort study. J Int AIDS Soc. 2020;23(7):e25550.
   PubMed Web of Science ®Google Scholar
• Konstantopoulos C, Ribaudo H, Ragland K, et al. Antiretroviral regimen and suboptimal medication adherence are associated with low-level human immunodeficiency virus viremia. Open Forum Infect Dis. 2015;2(1):ofu119.
   PubMed Web of Science ®Google Scholar
• Pasternak AO, Bruin M, Bakker M, et al. Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of virological rebound in plasma. J Infect Dis. 2012;206(9):1443–1452.
   PubMed Web of Science ®Google Scholar
• Li JZ, Gallien S, Ribaudo H, et al. Incomplete adherence to antiretroviral therapy is associated with higher levels of residual HIV-1 viremia. AIDS. 2014;28(2):181–186.
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Di Filippo E, Comi L, et al. Reduced adherence to antiretroviral therapy is associated with residual low-level viremia. Pragmat Obs Res. 2017;8:91–97.
   PubMed Web of Science ®Google Scholar
• Pereira R, Ludwig DA, Mathew S, et al. Predicting viral failure in human immunodeficiency virus perinatally infected youth with persistent low-level viremia on highly active antiretroviral therapy. J Pediatric Infect Dis Soc. 2019;8(4):303–309.
   PubMed Web of Science ®Google Scholar
• Jordan MR, Winsset, Tiro A, et al. HIV Drug Resistance Profiles and Clinical Outcomes in Patients with Viremia Maintained at Very Low Levels. World J AIDS. 2013;3(2):71–78.
   Google Scholar
• Taramasso L, Magnasco L, Bruzzone B, et al. How relevant is the HIV low level viremia and how is its management changing in the era of modern ART? A large cohort analysis. J Clin Virol. 2020;123:104255.
   PubMed Web of Science ®Google Scholar
• Villalobos C, Ceballos ME, Ferrés M, et al. Drug resistance mutations in proviral DNA of HIV-infected patients with low level of viremia. J Clin Virol. 2020;132:104657.
   PubMed Web of Science ®Google Scholar
• Grennan JT, Loutfy MR, Su D, et al. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis. 2012;205(8):1230–1238.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). HIV DRUG RESISTANCE REPORT. 2017. Accessed 2021 Sept 10 https://apps.who.int/iris/bitstream/handle/10665/255896/9789241512831-eng.pdf
   Google Scholar
• World Health Organization (WHO). GLOBAL ACTION PLAN ON HIV DRUG RESISTANCE 2017-2021. https://www.who.int/publications/i/item/978-92-4-151284-8. Accessed 2021 Sept 10
   Google Scholar
• Santoro MM, Fabeni L, Armenia D, et al. Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels. Clin Infect Dis. 2014;58(8):1156–1164.
   PubMed Web of Science ®Google Scholar
• Mackie NE, Phillips A-N, Kaye S, et al. Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. J Infect Dis. 2010;201(9):1303–1307.
   PubMed Web of Science ®Google Scholar
• Armenia D, Zaccarelli M, Borghi V, et al. Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment. J Clin Virol. 2018;104:61–64.
   PubMed Web of Science ®Google Scholar
• Palich R, Wirden M, Peytavin G, et al. Persistent low-level viraemia in antiretroviral treatment-experienced patients is not linked to viral resistance or inadequate drug concentrations. J Antimicrob Chemother. 2020;75(10):2981–2985.
   Web of Science ®Google Scholar
• Vancoillie L, et al. Drug resistance is rarely the cause or consequence of long-term persistent low-level viraemia in HIV-1-infected patients on ART. Antivir Ther. 2015;20(8):789–794.
   PubMed Web of Science ®Google Scholar
• Inzaule SC, Bertagnolio S, Kityo CM, et al. The relative contributions of HIV drug resistance, nonadherence and low-level viremia to viremic episodes on antiretroviral therapy in sub-Saharan Africa. AIDS. 2020;34(10):1559–1566.
   PubMed Web of Science ®Google Scholar
• Gandhi RT, Zheng L, Bosch R-J, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med. 2010;7(8):e1000321.
   PubMed Web of Science ®Google Scholar
• McMahon D, Jones J, Wiegand A, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis. 2010;50(6):912–919.
   PubMed Web of Science ®Google Scholar
• Cheng CY, Luo Y-Z, Wu P-Y, et al. Antiretroviral therapy (ART) management of low-level viremia in taiwan (ALLEVIATE). J Int AIDS Soc. 2014;17(4 Suppl 3):19785.
   PubMed Web of Science ®Google Scholar
• Paton NI, Kityo C, Thompson J, et al. Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial. Lancet HIV. 2017 e341-e348; 41: 10.1016/S2352-3018(17)30065-6
   Google Scholar
• Amstutz A, Nsakala BL, Vanobberghen F, et al. Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: an open-label randomized controlled trial in Lesotho. PLoS Med. 2020;17(9):e1003325.
   PubMed Web of Science ®Google Scholar
• Brown JA, Amstutz A, Nsakala B-L, et al. Extensive drug resistance during low-level HIV viraemia while taking NNRTI-based ART supports lowering the viral load threshold for regimen switch in resource-limited settings: a pre-planned analysis from the SESOTHO trial. J Antimicrob Chemother; 2021.
   Google Scholar
• Chen G-J, Sun H-Y, Chang S-Y, et al. Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy. Int J Infect Dis. 2021;105:147–151.
   Web of Science ®Google Scholar
• Elvstam O, et al. All-cause mortality and serious non-AIDS events in adults with low-level hiv viremia during combination antiretroviral therapy: results from a Swedish nationwide observational study. Clin Infect Dis. 2020;72:2079–2086.
   Web of Science ®Google Scholar
• Zhang S, van Sighem A, Gras L, et al. Clinical significance of transient HIV type-1 viraemia and treatment interruptions during suppressive antiretroviral treatment. Antivir Ther. 2010;15(4):555–562.
   PubMed Web of Science ®Google Scholar
• Quiros-Roldan E, Raffetti E, Castelli F, et al. Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: a MASTER cohort study. J Antimicrob Chemother. 2016;71(12):3519–3527.
   PubMedGoogle Scholar
• Eastburn A, Scherzer R, Zolopa AR, et al. Association of low level viremia with inflammation and mortality in HIV-infected adults. PLoS One. 2011;6(11):e26320.
   PubMed Web of Science ®Google Scholar
• Elvstam O, Medstrand P, Jansson M, et al. Is low-level HIV1 viraemia associated with elevated levels of markers of immune activation, coagulation and cardiovascular disease? HIV Med. 2019;20(9):571–580.
   PubMed Web of Science ®Google Scholar
• Reus S, Portilla J, Sánchez-Payá J, et al. Low-level HIV viremia is associated with microbial translocation and inflammation. J Acquir Immune Defic Syndr. 2013;62(2):129–134.
   PubMed Web of Science ®Google Scholar
• Poizot-Martin I, Faucher O, Obry-Roguet V, et al. Lack of correlation between the size of HIV proviral DNA reservoir and the level of immune activation in HIV-infected patients with a sustained undetectable HIV viral load for 10 years. J Clin Virol. 2013;57(4):351–355.
   PubMed Web of Science ®Google Scholar
• Schuler PJ, Macatangay BJC, Saze Z, et al. CD4⁺CD73⁺ T cells are associated with lower T-cell activation and C reactive protein levels and are depleted in HIV-1 infection regardless of viral suppression. AIDS. 2013;27(10):1545–1555.
   PubMed Web of Science ®Google Scholar
• Giorgi JV, Hultin L, McKeating J, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis. 1999;179(4):859–870.
   PubMed Web of Science ®Google Scholar
• Leng Q, Borkow G, Weisman Z, et al. Immune activation correlates better than HIV plasma viral load with CD4 T-cell decline during HIV infection. J Acquir Immune Defic Syndr. 2001;27(4):389–397.
   PubMed Web of Science ®Google Scholar
• Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5(10):e203.
   PubMed Web of Science ®Google Scholar
• Tien PC, Choi AI, Zolopa AR, et al. Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr. 2010;55(3):316–322.
   PubMed Web of Science ®Google Scholar
• Han J, Mu W, Zhao H, et al. HIV-1 low-level viremia affects T cell activation rather than T cell development in school-age children, adolescents, and young adults during antiretroviral therapy. Int J Infect Dis. 2020;91:210–217.
   PubMed Web of Science ®Google Scholar
• Falasca F, Di Carlo D, De Vito C, et al. Evaluation of HIV-DNA and inflammatory markers in HIV-infected individuals with different viral load patterns. BMC Infect Dis. 2017;17(1):581.
   PubMed Web of Science ®Google Scholar
• Lu J, Ma -S-S, Zhang W-Y, et al. Changes in peripheral blood inflammatory factors (TNF-α and IL-6) and intestinal flora in AIDS and HIV-positive individuals. J Zhejiang Univ Sci B. 2019;20(10):793–802.
   PubMed Web of Science ®Google Scholar
• Bastard J-P, Soulié C, Fellahi S, et al. Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients. Antivir Ther. 2012;17(5):915–919.
   PubMed Web of Science ®Google Scholar
• Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12(12):1365–1371.
   PubMed Web of Science ®Google Scholar
• Ciccone EJ, Read SW, Mannon PJ, et al. Cycling of gut mucosal CD4+ T cells decreases after prolonged anti-retroviral therapy and is associated with plasma LPS levels. Mucosal Immunol. 2010;3(2):172–181.
   PubMed Web of Science ®Google Scholar
• Cassol E, Malfeld S, Mahasha P, et al. Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy. J Infect Dis. 2010;202(5):723–733.
   PubMed Web of Science ®Google Scholar
• Jiang W, Lederman M, Hunt P, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis. 2009;199(8):1177–1185.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382(9903):1525–1533.
   PubMed Web of Science ®Google Scholar
• Louie JK, Hsu L, Osmond D, et al. Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-1998. J Infect Dis. 2002;186(7):1023–1027.
   PubMed Web of Science ®Google Scholar
• Lewden C, Salmon D, Morlat P, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol. 2005;34(1):121–130.
   PubMed Web of Science ®Google Scholar
• Neuhaus J, Angus B, Kowalska JD, et al. Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS. 2010;24(5):697–706.
   PubMed Web of Science ®Google Scholar
• Ingle SM, May MT, Gill MJ, et al. Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients. Clin Infect Dis. 2014;59(2):287–297.
   PubMed Web of Science ®Google Scholar
• Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014;384(9939):241–248.
   PubMed Web of Science ®Google Scholar
• Wong C, Gange SJ, Moore RD, et al. Multimorbidity among persons living with human immunodeficiency virus in the united states. Clin Infect Dis. 2018;66(8):1230–1238.
   PubMed Web of Science ®Google Scholar
• Crum-Cianflone N, Hullsiek KH, Marconi V, et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS. 2009;23(1):41–50.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Reiss P, Gasiorowski J, et al. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr. 2010;55(2):262–270.
   PubMed Web of Science ®Google Scholar
• Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2011;53(11):1130–1139.
   PubMed Web of Science ®Google Scholar
• Marin B, Thiébaut R, Bucher HC, et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS. 2009;23(13):1743–1753.
   PubMed Web of Science ®Google Scholar
• Moore RD, Gebo K, Lucas G, et al. Rate of comorbidities not related to HIV infection or AIDS among HIV-infected patients, by CD4 cell count and HAART use status. Clin Infect Dis. 2008;47(8):1102–1104.
   PubMed Web of Science ®Google Scholar
• Monforte A, Abrams D, Pradier C, et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS. 2008;22(16):2143–2153.
   PubMed Web of Science ®Google Scholar
• Weber R, Sabin C, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166(15):1632–1641.
   PubMed Web of Science ®Google Scholar
• Friis-Møller N, Reiss P, Sabin C, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17):1723–1735.
   PubMed Web of Science ®Google Scholar
• Obel N, Thomsen HF, Kronborg G, et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis. 2007;44(12):1625–1631.
   PubMed Web of Science ®Google Scholar
• Krishnan S, Schouten JT, Jacobson DL, et al. Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis. Oncology. 2011;80(1–2):42–49.
   PubMed Web of Science ®Google Scholar
• van Lelyveld SFL, Gras L, Kesselring A, et al. Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort. AIDS. 2012;26(4):465–474.
   PubMed Web of Science ®Google Scholar
• Engsig FN, Zangerle R, Katsarou O, et al. Long-term mortality in HIV-Positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin Infect Dis. 2014;58(9):1312–1321.
   PubMed Web of Science ®Google Scholar
• Baker JV, Peng G, Rapkin J, et al. Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases. J Acquir Immune Defic Syndr. 2008;48(5):541–546.
   PubMed Web of Science ®Google Scholar
• Pacheco YM, Jarrin I, Rosado I, et al. Increased risk of non-AIDS-related events in HIV subjects with persistent low CD4 counts despite cART in the CoRIS cohort. Antiviral Res. 2015;117:69–74.
   PubMed Web of Science ®Google Scholar
• Ma Q, Vaida F, Wong J, et al. Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients. J Neurovirol. 2016;22(2):170–178.
   PubMed Web of Science ®Google Scholar
• Samuels R, Bayerri CR, Sayer JA, et al. Tenofovir disoproxil fumarate-associated renal tubular dysfunction: noninvasive assessment of mitochondrial injury. AIDS. 2017;31(9):1297–1301.
   PubMed Web of Science ®Google Scholar
• Martin AM, Hammond E, Nolan D, et al. Accumulation of mitochondrial DNA mutations in human immunodeficiency virus-infected patients treated with nucleoside-analogue reverse-transcriptase inhibitors. Am J Hum Genet. 2003;72(3):549–560.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Song F, Gao Z, et al. Long-term exposure of mice to nucleoside analogues disrupts mitochondrial DNA maintenance in cortical neurons. PLoS One. 2014;9(1):e85637.
   PubMed Web of Science ®Google Scholar
• Côté HCF, Brumme ZL, Craib KJP, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med. 2002;346(11):811–820.
   PubMed Web of Science ®Google Scholar
• Soontornniyomkij V, Umlauf A, Chung SA, et al. HIV protease inhibitor exposure predicts cerebral small vessel disease. AIDS. 2014;28(9):1297–1306.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Mehta SH, Chaisson RE, et al. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS. 2004;18(17):2277–2284.
   PubMed Web of Science ®Google Scholar
• Dauchy F-A, Lawson-Ayayi S, de La Faille R, et al. Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy. Kidney Int. 2011;80(3):302–309.
   PubMed Web of Science ®Google Scholar
• Roca-Bayerri C, Robertson F, Pyle A, et al. Mitochondrial DNA damage and brain aging in human immunodeficiency virus. Clin Infect Dis. 2021;73(2): e466-e473. doi:10.1093/cid/ciaa984.
   PubMed Web of Science ®Google Scholar
• D’ Ettorre G, Ceccarelli G, Pavone P, et al. What happens to cardiovascular system behind the undetectable level of HIV viremia? AIDS Res Ther. 2016;13(1):21.
   PubMed Web of Science ®Google Scholar
• Zhang S, van Sighem A, Kesselring A, et al. Episodes of HIV viremia and the risk of non-AIDS diseases in patients on suppressive antiretroviral therapy. J Acquir Immune Defic Syndr. 2012;60(3):265–272.
   PubMed Web of Science ®Google Scholar
• Hsue PY, Scherzer R, Hunt P-H, et al. Carotid intima-media thickness progression in HIV-infected adults occurs preferentially at the carotid bifurcation and is predicted by inflammation. J Am Heart Assoc. 2012;1(2):e000422.
   Web of Science ®Google Scholar
• Ramratnam B, Mittler JE, Zhang L, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med. 2000;6(1):82–85.
   PubMed Web of Science ®Google Scholar
• Fourati S, Flandre P, Calin R, et al. Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy. J Antimicrob Chemother. 2014;69(3):753–756.
   PubMed Web of Science ®Google Scholar
• Parisi SG, Andreis S, Mengoli C, et al. Baseline cellular HIV DNA load predicts HIV DNA decline and residual HIV plasma levels during effective antiretroviral therapy. J Clin Microbiol. 2012;50(2):258–263.
   PubMed Web of Science ®Google Scholar
• Chun T-W, Justement JS, Murray D, et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS. 2010;24(18):2803–2808.
   PubMed Web of Science ®Google Scholar
• Simonetti FR, Sobolewski MD, Fyne E, et al. Clonally expanded CD4 + T cells can produce infectious HIV-1 in vivo. Proc Natl Acad Sci U S A. 2016;113(7):1883–1888.
   PubMed Web of Science ®Google Scholar
• Bui JK, Sobolewski MD, Keele BF, et al. Proviruses with identical sequences comprise a large fraction of the replication-competent HIV reservoir. PLoS Pathog. 2017;13(3):e1006283.
   PubMed Web of Science ®Google Scholar
• Hosmane NN, Kwon KJ, Bruner KM, et al. Proliferation of latently infected CD4. J Exp Med. 2017;214(4):959–972.
   PubMed Web of Science ®Google Scholar
• Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5(5):512–517.
   PubMed Web of Science ®Google Scholar
• Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278(5341):1295–1300.
   PubMed Web of Science ®Google Scholar
• Chun TW, Moir S, Fauci AS. HIV reservoirs as obstacles and opportunities for an HIV cure. Nat Immunol. 2015;16(6):584–589.
   PubMed Web of Science ®Google Scholar
• Chun T-W, Nickle D, Justement J, et al. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis. 2008;197(5):714–720.
   PubMed Web of Science ®Google Scholar
• Chun T-W, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997;94(24):13193–13197.
   PubMed Web of Science ®Google Scholar
• Wong JK, Hezareh M, Günthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997;278(5341):1291–1295.
   PubMed Web of Science ®Google Scholar
• Chun TW, Nickle D, Justement J-S, et al. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest. 2005;115(11):3250–3255.
   PubMed Web of Science ®Google Scholar
• Crooks AM, Bateson R, Cope AB, et al. Precise quantitation of the latent HIV-1 reservoir: implications for eradication strategies. J Infect Dis. 2015;212(9):1361–1365.
   PubMed Web of Science ®Google Scholar
• Pinzone MR, VanBelzen DJ, Weissman S, et al. Longitudinal HIV sequencing reveals reservoir expression leading to decay which is obscured by clonal expansion. Nat Commun. 2019;10(1):728.
   PubMed Web of Science ®Google Scholar
• Pinzone MR, Graf E, Lynch L, et al. Monitoring integration over time supports a role for cytotoxic T lymphocytes and ongoing replication as determinants of reservoir size. J Virol. 2016;90(23):10436–10445.
   PubMed Web of Science ®Google Scholar
• Murray JM, McBride K, Boesecke C, et al. Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards. AIDS. 2012;26(5):543–550.
   PubMed Web of Science ®Google Scholar
• Yukl SA, Gianella S, Sinclair E, et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis. 2010;202(10):1553–1561.
   PubMed Web of Science ®Google Scholar
• Sarmati L, D’Ettorre G, Parisi S, et al. HIV replication at low copy number and its correlation with the HIV reservoir: a clinical perspective. Curr HIV Res. 2015;13(3):250–257.
   PubMed Web of Science ®Google Scholar
• Jacobs JL, Halvas EK, Tosiano MA, et al. Persistent HIV-1 viremia on antiretroviral therapy: measurement and mechanisms. Front Microbiol. 2019;10:2383.
   PubMed Web of Science ®Google Scholar
• Widera M, Dirks M, Bleekmann B, et al. HIV-1 persistent viremia is frequently followed by episodes of low-level viremia. Med Microbiol Immunol. 2017;206(3):203–215.
   PubMed Web of Science ®Google Scholar
• Jacobs JL, Tosiano MA, Koontz DL, et al. Automated, multi-replicate quantification of persistent HIV-1 viremia in individuals on antiretroviral therapy. J Clin Microbiol. 2020;58. DOI:10.1128/JCM.01442-20.
   Web of Science ®Google Scholar
• Wagner TA, McLaughlin S, Garg K, et al. HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science. 2014;345(6196):570–573.
   PubMed Web of Science ®Google Scholar
• Cesana D, Santoni de Sio FR, Rudilosso L, et al. HIV-1-mediated insertional activation of STAT5B and BACH2 trigger viral reservoir in T regulatory cells. Nat Commun. 2017;8(1):498.
   PubMed Web of Science ®Google Scholar
• Maldarelli F, Wu X, Su L, et al. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science. 2014;345(6193):179–183.
   PubMed Web of Science ®Google Scholar
• Ikeda T, Shibata J, Yoshimura K, et al. Recurrent HIV-1 Integration at the BACH2 locus in resting CD4 + T cell populations during effective highly active antiretroviral therapy. J Infect Dis. 2007;195(5):716–725.
   PubMed Web of Science ®Google Scholar
• McManus WR, Bale MJ, Spindler J, et al. HIV-1 in lymph nodes is maintained by cellular proliferation during antiretroviral therapy. J Clin Invest. 2019;130:4629–4642.
   Web of Science ®Google Scholar
• Reeves DB, Duke ER, Wagner TA, et al. A majority of HIV persistence during antiretroviral therapy is due to infected cell proliferation. Nat Commun. 2018;9(1):4811.
   PubMed Web of Science ®Google Scholar
• Charpentier C, Landman R, Laouenan C, et al. Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome. J Antimicrob Chemother. 2012;67(9):2231–2235.
   PubMed Web of Science ®Google Scholar
• Bailey JR, Sedaghat AR, Kieffer T, et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4 + T Cells. J Virol. 2006;80(13):6441–6457.
   PubMed Web of Science ®Google Scholar
• Wagner TA, McKernan JL, Tobin NH, et al. An increasing proportion of monotypic HIV-1 DNA sequences during antiretroviral treatment suggests proliferation of HIV-infected cells. J Virol. 2013;87(3):1770–1778.
   PubMed Web of Science ®Google Scholar
• Chun T-W, Murray D, Justement JS, et al. Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis. 2011;204(1):135–138.
   PubMed Web of Science ®Google Scholar
• Avettand-Fènoël V, Hocqueloux L, Ghosn J, et al. Total HIV-1 DNA, a marker of viral reservoir dynamics with clinical implications. Clin Microbiol Rev. 2016;29(4):859–880.
   PubMed Web of Science ®Google Scholar
• Bachmann N, Von Siebenthal C, Vongrad V, et al. Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART. Nat Commun. 2019;10(1):3193.
   PubMed Web of Science ®Google Scholar